Abstract |
The prognostic impact of trisomy 8, alone or with other clonal aberrations, was evaluated in 849 patients with previously untreated acute myeloid leukemia (AML) who were registered to 5 Southwest Oncology Group trials. At presentation, 108 (12.7%) patients had +8 in their karyotypes, including 43 (5.1%) patients with +8 as the sole aberration; 307 (36.2%) were normal, and 434 (51.1%) had other cytogenetic abnormalities. Patients with +8 were slightly older (P =.033), had lower WBC (P =.011), and had lower percentages of peripheral blasts (P =.0004) than the patients without +8. Median survival time for all patients with +8 was 9.9 months (95% CI, 6.5-12.5), similar to that of "unfavorable" cytogenetics risk groups (8.3 months; 95% CI, 6.8-9.5.) Patients with +8 had significantly lower peripheral blasts (P =.0002), WBC (P <.0001) counts, and decreased overall survival (OS) than patients with normal cytogenetics (9.9 months vs 15.4 months; P =.006). However, survival of patients with +8 as the sole aberration did not differ significantly from those with normal cytogenetics (P =.36). Thus, the trisomy 8 group as a whole had poor survival, which was largely attributable to worsened outcomes among patients whose trisomy 8 was associated with other unfavorable cytogenetic abnormalities.
|
Authors | Sandra R Wolman, Holly Gundacker, Frederick R Appelbaum, Marilyn L Slovak, Southwest Oncology Group |
Journal | Blood
(Blood)
Vol. 100
Issue 1
Pg. 29-35
(Jul 01 2002)
ISSN: 0006-4971 [Print] United States |
PMID | 12070004
(Publication Type: Comparative Study, Journal Article, Research Support, U.S. Gov't, P.H.S.)
|
Topics |
- Acute Disease
- Adolescent
- Adult
- Aged
- Aged, 80 and over
- Chromosomes, Human, Pair 8
(genetics)
- Cytogenetic Analysis
- Female
- Humans
- Leukemia, Myeloid
(epidemiology, genetics, mortality)
- Male
- Middle Aged
- Prognosis
- Risk Factors
- Southwestern United States
- Survival Analysis
- Treatment Outcome
- Trisomy
(pathology)
|